Scarica l'app Stockscreener
30.04
0.02%
0.17
Precedente Chiudi:
$30.21
Aprire:
$29.73
Volume 24 ore:
82,230
Relative Volume:
0.53
Capitalizzazione di mercato:
$431.23M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+30.86%
1M Prestazione:
+59.03%
6M Prestazione:
+174.68%
1 anno Prestazione:
-38.87%
Intervallo 1D:
$29.01
$31.12
Intervallo di 1 settimana:
$22.02
$32.55
Portata 52W:
$6.875
$74.49
Neurogene Inc Stock (NGNE) Company Profile
Nome
Neurogene Inc
Settore
Industria
Telefono
(877) 237-5020
Indirizzo
535 W 24TH STREET, NEW YORK
Confronta NGNE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NGNE
Neurogene Inc
|
30.21 | 431.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
406.76 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.17 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.62 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
809.47 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.09 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Neurogene Inc Stock (NGNE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Craig Hallum | Buy |
| 2025-05-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-06-11 | Iniziato | Robert W. Baird | Outperform |
| 2024-04-29 | Iniziato | Leerink Partners | Outperform |
| 2024-03-21 | Iniziato | William Blair | Outperform |
| 2024-01-08 | Iniziato | H.C. Wainwright | Buy |
| 2024-01-05 | Iniziato | Stifel | Buy |
| 2024-01-04 | Iniziato | TD Cowen | Outperform |
Mostra tutto
Neurogene Inc Borsa (NGNE) Ultime notizie
Can a trend reversal in Neurogene Inc. lead to recoveryWeekly Stock Recap & Growth Focused Entry Reports - newser.com
Price action breakdown for Neurogene Inc.Trade Volume Report & Capital Efficiency Focused Strategies - newser.com
How to track smart money flows in Neurogene Inc.July 2025 Big Picture & High Return Stock Watch Alerts - newser.com
Why Neurogene Inc. stock is popular among millennials2025 Big Picture & Advanced Swing Trade Entry Plans - newser.com
Does Neurogene Inc. qualify in momentum factor screeningProduct Launch & Reliable Price Action Trade Plans - newser.com
Why Neurogene Inc. stock remains a top recommendationQuarterly Market Summary & Verified Swing Trading Watchlist - newser.com
Neurogene’s (NGNE) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Neurogene (NASDAQ:NGNE) - MarketBeat
Neurogene (NASDAQ:NGNE) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
How Neurogene Inc. (UU8) stock responds to job market shiftsJuly 2025 Sector Moves & High Win Rate Trade Tips - newser.com
HC Wainwright & Co. Reiterates Neurogene (NGNE) Buy Recommendation - Nasdaq
Neurogene Reaches Accord With FDA on Plan for Registrational Trial for Rett Syndrome Gene Therapy NGN-401 - CGTLive®
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Fourth Quarter of 2025 - MarketScreener
Neurogene to begin Rett syndrome gene therapy registrational trial in Q4 - Investing.com
Real time pattern detection on Neurogene Inc. stockQuarterly Trade Summary & Advanced Swing Trade Entry Alerts - newser.com
Neurogene Completes FDA Talks for Rett Syndrome Trial - TipRanks
Neurogene : Poster ESGCT2025 RoA Final Print - MarketScreener
23 developmental milestones — Neurogene to start Embolden dosing in Q4 2025 after FDA talks and ICV data - Stock Titan
What recovery options are there for Neurogene Inc.2025 Top Gainers & Low Risk Entry Point Guides - newser.com
Forecasting Neurogene Inc. price range with options dataTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
What drives Neurogene Inc UU8 stock priceBollinger Bands Signals & Free Explosive Wealth Accumulation - earlytimes.in
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference - Stock Titan
What analysts say about Neurogene Inc stockInflation Impact on Stocks & Big Data Market Reports - earlytimes.in
Short interest data insights for Neurogene Inc.July 2025 Highlights & Entry Point Confirmation Signals - newser.com
Is Neurogene Inc a good long term investmentWeekly Market Snapshot & Free Rapid Profit Acceleration - earlytimes.in
Neurogene Insiders Placed Bullish Bets Worth US$1.46m - simplywall.st
Strategies to average down on Neurogene Inc.Portfolio Performance Summary & Free Fast Gain Swing Trade Alerts - newser.com
Long term hold vs stop loss in Neurogene Inc.2025 Year in Review & Momentum Based Trading Ideas - newser.com
Neurogene announces inducement grants under Nasdaq Listing Rule - MarketScreener
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
We're Not Very Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Rate - 富途牛牛
Developing predictive dashboards with Neurogene Inc. dataQuarterly Market Review & Weekly Return Optimization Plans - newser.com
Does Neurogene Inc. stock trade at a discount to peersJuly 2025 Patterns & Free Community Consensus Stock Picks - newser.com
Is Neurogene Inc. trending in predictive chart modelsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Neurogene looks ‘deeply undervalued’ after Taysha news, says H.C. Wainwright - TipRanks
Batten Disease Pipeline 2025: Innovative Clinical Developments by 10+ Global Leaders – DelveInsight | Featuring Polaryx Therapeutics, Neurogene, Theranexus, M6P Therapeutics, Regenxbio - The Globe and Mail
Neurogene Inc Azioni (NGNE) Dati Finanziari
Non sono disponibili dati finanziari per Neurogene Inc (NGNE). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
0.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):